Trading of Bio-Rad Laboratories was halted at 12:19 PM EST due to "LULD pause". Bio-Rad Laboratories (BIO.B) Competitors $247.05 0.00 (0.00%) As of 08/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock BIO.B vs. VLTO, TER, FTV, RVTY, NVMI, AVTR, VNT, RAL, MIR, and STShould you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Veralto (VLTO), Teradyne (TER), Fortive (FTV), Revvity (RVTY), Nova (NVMI), Avantor (AVTR), Vontier (VNT), Ralliant (RAL), Mirion Technologies (MIR), and Sensata Technologies (ST). These companies are all part of the "measuring and control equipment" industry. Bio-Rad Laboratories vs. Its Competitors Veralto Teradyne Fortive Revvity Nova Avantor Vontier Ralliant Mirion Technologies Sensata Technologies Bio-Rad Laboratories (NYSE:BIO.B) and Veralto (NYSE:VLTO) are both measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Which has better valuation & earnings, BIO.B or VLTO? Veralto has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Veralto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Rad Laboratories$2.57B2.62-$1.84B$11.7321.06Veralto$5.19B5.20$833M$3.5830.39 Do institutionals & insiders have more ownership in BIO.B or VLTO? 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 91.3% of Veralto shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.4% of Veralto shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend BIO.B or VLTO? Veralto has a consensus target price of $114.00, indicating a potential upside of 4.79%. Given Veralto's stronger consensus rating and higher probable upside, analysts plainly believe Veralto is more favorable than Bio-Rad Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Veralto 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has more volatility & risk, BIO.B or VLTO? Bio-Rad Laboratories has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Veralto has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Does the media prefer BIO.B or VLTO? In the previous week, Veralto had 14 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 14 mentions for Veralto and 0 mentions for Bio-Rad Laboratories. Veralto's average media sentiment score of 1.53 beat Bio-Rad Laboratories' score of 0.00 indicating that Veralto is being referred to more favorably in the news media. Company Overall Sentiment Bio-Rad Laboratories Neutral Veralto Very Positive Is BIO.B or VLTO more profitable? Veralto has a net margin of 16.65% compared to Bio-Rad Laboratories' net margin of 12.50%. Veralto's return on equity of 41.45% beat Bio-Rad Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Bio-Rad Laboratories12.50% 4.01% 2.82% Veralto 16.65%41.45%14.05% SummaryVeralto beats Bio-Rad Laboratories on 14 of the 16 factors compared between the two stocks. Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIO.B vs. The Competition Export to ExcelMetricBio-Rad LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$6.72B$3.03B$5.50B$20.82BDividend YieldN/A2.28%4.59%3.65%P/E Ratio21.0617.6029.9728.42Price / Sales2.62353.42445.5259.91Price / Cash23.7740.7324.8117.60Price / Book1.059.028.704.66Net Income-$1.84B-$54.75M$3.26B$994.60M7 Day PerformanceN/A-0.72%0.53%1.23%1 Month Performance-4.15%7.61%3.29%0.22%1 Year Performance-24.40%23.83%45.87%17.65% Bio-Rad Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIO.BBio-Rad LaboratoriesN/A$247.05flatN/A-24.4%$6.72B$2.57B21.068,200VLTOVeralto2.0397 of 5 stars$106.64-0.3%$114.00+6.9%+1.0%$26.47B$5.19B29.8017,000Positive NewsTERTeradyne4.6013 of 5 stars$106.61+0.8%$114.44+7.3%-14.0%$17.02B$2.82B36.726,500Positive NewsFTVFortive4.885 of 5 stars$48.01+1.7%$65.86+37.2%-32.1%$16.23B$6.23B21.6118,000News CoveragePositive NewsRVTYRevvity2.9969 of 5 stars$89.01+0.8%$120.07+34.9%-27.7%$10.48B$2.80B37.6711,000Positive NewsNVMINova1.4259 of 5 stars$270.95-0.7%$282.50+4.3%+20.8%$7.97B$672.40M40.934,149News CoveragePositive NewsEarnings ReportAnalyst RevisionAVTRAvantor4.5114 of 5 stars$11.36+0.5%$15.50+36.4%-51.5%$7.76B$6.78B11.5113,500News CoverageVNTVontier4.2076 of 5 stars$41.67+1.1%$46.71+12.1%+20.7%$6.11B$2.98B15.848,000RALRalliantN/A$43.03+0.2%$57.00+32.5%N/A$4.86BN/A0.007,000News CoverageEarnings ReportDividend AnnouncementMIRMirion Technologies1.1135 of 5 stars$21.00+0.9%$22.25+5.9%+108.2%$4.86B$860.80M698.502,860Positive NewsAnalyst DowngradeSTSensata Technologies4.7698 of 5 stars$30.36+0.7%$34.64+14.1%-18.3%$4.42B$3.75B40.4519,000 Related Companies and Tools Related Companies VLTO Competitors TER Competitors FTV Competitors RVTY Competitors NVMI Competitors AVTR Competitors VNT Competitors RAL Competitors MIR Competitors ST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BIO.B) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Rad Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access